UH engineers helped develop an mRNA-based strategy that boosts cancer-fighting T cells and, in mouse studies, helped ...
Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) cells IGI’s clinically validated BEAT® platform enabled ...
Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...
Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response ...
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic ...
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Ichnos Glenmark Innovation announces new development candidate, ISB 2301, a first-in-class multispecific immune cells activator targeting solid tumours: Our Bureau, Mumbai Wednesd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results